All In Biotech

Drug Trial Radar · NCT07449702

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Feb 23, 2026

Primary completion

May 2030

Study completion Jul 2030

Sponsor

Lead sponsor
Oruka Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Conditions

  • Plaque Psoriasis

Interventions

  • ORKA-001Drug

    ORKA-001 administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)Time frame: Day 1 through Week 144

Locations

39 sites in 2 countries. Site status is shown where the registry gives one.

  • Oruka Therapeutics Investigative Site

    Phoenix, Arizona · Recruiting

  • Oruka Therapeutics Investigative Site

    North Little Rock, Arkansas · Recruiting

  • Oruka Therapeutics Investigative Site

    Fountain Valley, California · Recruiting

  • Oruka Therapeutics Investigative Site

    Los Angeles, California · Recruiting

  • Oruka Therapeutics Investigative Site

    Los Angeles, California · Recruiting

  • Oruka Therapeutics Investigative Site

    San Diego, California · Recruiting

  • Oruka Therapeutics Investigative Site

    Santa Ana, California · Recruiting

  • Oruka Therapeutics Investigative Site

    Santa Monica, California · Recruiting

  • Oruka Therapeutics Investigative Site

    Cromwell, Connecticut · Recruiting

  • Oruka Therapeutics Investigative Site

    Miami, Florida · Recruiting

  • Oruka Therapeutics Investigative Site

    Rolling Meadows, Illinois · Recruiting

  • Oruka Therapeutics Investigative Site

    Plainfield, Indiana · Recruiting

  • Oruka Therapeutics Investigative Site

    Bowling Green, Kentucky · Recruiting

  • Oruka Therapeutics Investigative Site

    Rockville, Maryland · Recruiting

  • Oruka Therapeutics Investigative Site

    Boston, Massachusetts · Recruiting

  • Oruka Therapeutics Investigative Site

    Detroit, Michigan · Recruiting

  • Oruka Therapeutics Investigative Site

    New York, New York · Recruiting

  • Oruka Therapeutics Investigative Site

    New York, New York · Recruiting

  • Oruka Therapeutics Investigative Site

    Cleveland, Ohio · Recruiting

  • Oruka Therapeutics Investigative Site

    Mason, Ohio · Recruiting

  • Oruka Therapeutics Investigative Site

    Portland, Oregon · Recruiting

  • Oruka Therapeutics Investigative Site

    Portland, Oregon · Recruiting

  • Oruka Therapeutics Investigative Site

    Frisco, Texas · Recruiting

  • Oruka Therapeutics Investigative Site

    Houston, Texas · Recruiting

  • Oruka Therapeutics Investigative Site

    Webster, Texas · Recruiting

  • Oruka Therapeutics Investigative Site

    Norfolk, Virginia · Recruiting

  • Oruka Therapeutics Investigative Site

    Edmonton, Alberta, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Edmonton, Alberta, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Surrey, British Columbia, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Surrey, British Columbia, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Fredericton, New Brunswick, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Ajax, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    London, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Markham, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Peterborough, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Waterloo, Ontario, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Oruka Therapeutics Investigative Site

    Québec, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.